• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

    5/2/25 8:30:00 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRAX alert in real time by email

    On track for six major study readouts across four programs over the next 12 months

    Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen

    Vormatrigine continues to generate a best-in-class safety profile with new data demonstrating no food effect and higher dosing tolerability

    Praxis to host a virtual investor event on Friday, May 2, 2025 to discuss its DEE portfolio [registration link]

    Cash and investments of $472 million as of March 31, 2025, maintains runway into 2028

    BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the first quarter 2025.

    "We have made substantial progress in advancing our promising late-stage epilepsy portfolio and are firing on all cylinders through this unpredictable time in the industry," said Marcio Souza, president and chief executive officer of Praxis. "With multiple upcoming catalysts and data readouts, we expect a transformative year at Praxis. In the near-term, we anticipate topline results for vormatrigine from the RADIANT study in epilepsy by mid-2025, and from the POWER1 study in the second half of 2025. Vormatrigine continues to demonstrate an ideal profile and strong competitive differentiation"

    Mr. Souza continued, "The registrational cohort of the EMBOLD study is recruiting strongly and is on-track for topline results no later than the first half of 2026, and we will soon initiate the registrational EMERALD study to investigate relutrigine more broadly in DEEs. The EMBRAVE study with elsunersen is progressing very well, with topline results expected in the first half of next year to support the registrational package, and we will initiate the Phase 3 EMBRAVE3 trial for elsunersen by mid-2025. While the interim analysis of Essential3 study 1 for ulixacaltamide was not what we expected, we are on track to complete both study 1 and study 2 for topline readout in the third quarter of this year. Our solid financial position ensures we have sufficient funding for all studies supporting our late-stage programs, with runway into 2028."

    Recent Highlights and Anticipated Milestones

    Cerebrum™ Small Molecule Platform

    • Vormatrigine for Focal Onset Seizures (FOS) and Generalized Epilepsy: An estimated 3.5 million people in the U.S. suffer from common epilepsies. Sodium channel therapy is the cornerstone of treatment for patients with epilepsy yet the currently approved drugs have significant safety and efficacy limitations. Vormatrigine is the most potent sodium-channel modulator ever designed to precisely target the hyperexcitable state of sodium-channels in adult common epilepsies.
      • At the American Association of Neurology (AAN) conference earlier this quarter, Praxis presented further data from recently completed Phase 1 studies [link], where vormatrigine continued to demonstrate an ideal profile with strong competitive differentiation.
        • Results from an additional 45 mg multiple ascending dose (MAD) cohort demonstrated a 20x exposure on the MES EC50 scale achieved in subjects, the most of any anti-seizure medicine, with a tolerable safety profile.
        • The Phase 1 food effect study demonstrated that food intake does not significantly impact vormatrigine absorption and therefore vormatrigine can be administered with or without food, which increases flexibility in dosing and ease of use for patients.
      • Enrollment and progress across the ENERGY program continues to advance
        • Praxis provided an update on the EMPOWER registrational study [link]at AAN, which continues to attract epilepsy patients and be a source for identifying candidate patients for the RADIANT and POWER1 studies, with over 3,000 patients registered to date
        • The RADIANT Phase 2 study in FOS and generalized epilepsy is progressing, with topline results expected mid-year 2025
        • The POWER1 Phase 2/3 registrational study for treatment resistant FOS is enrolling, with topline results expected in the second half of 2025
        • The POWER2 Phase 2/3 registrational study for treatment resistant FOS is on track to initiate in the second half of 2025



    • Relutrigine for DEEs: Relutrigine is a sodium channel modulator with therapeutic potential across developmental epilepsies. Relutrigine is currently being evaluated in the EMBOLD study in SCN2A and SCN8A DEEs, and we will be initiating the EMERALD study in a broader, pan-DEE patient population. Relutrigine has Rare Pediatric Disease Designation in three indications: SCN1A epilepsy (Dravet syndrome), SCN2A and SCN8A DEEs



      • The EMBOLD registrational cohort 2 continues to enroll strongly, with topline results expected no later than the first half of 2026, followed by potential NDA filing.
      • Praxis has completed discussions with the FDA on a trial for broad DEEs and will initiate the EMERALD registrational study in mid-2025. The study design will be shared at today's DEE virtual analyst event.



    • Ulixacaltamide for Essential Tremor (ET): ET is an inadequately managed, undertreated and high burden disease with a prevalence of seven million patients in the U.S. The Essential3 program is the first Phase 3 study in the disease and includes two registrational studies: Study 1 is a parallel design, placebo-controlled study (N=400) and Study 2 is a randomized withdrawal study (N=200). Since beginning recruitment in November 2023, over 200,000 patients have demonstrated interest in participating in the study.



      • On February 28, Praxis shared the results of a pre-planned interim analysis of Study 1. The Independent Data Monitoring Committee recommended that the study be stopped for futility, due to the results being unlikely to meet the primary efficacy endpoint under the parameters set by the statistical model.
      • Praxis has decided to continue the studies to completion and will share topline results in the third quarter of 2025. After reviewing the results of both studies, Praxis will make a decision if there is sufficient evidence to support an NDA filing.



    Solidus™ Antisense Oligonucleotide (ASO) Platform

    • Elsunersen for early-seizure-onset SCN2A DEE: SCN2A GoF-DEE is a rare, genetic epilepsy characterized by early-onset seizures and severe impact on development. Praxis has two studies supporting its registrational filing.
      • The EMBRAVE Part A Phase 1/2 study is continuing to enroll. Patients are randomized 3:1 drug to sham for a six-month period on a once-monthly dose, with the potential to escalate from 1 mg to 8 mg. Topline results are expected in the first half of 2026.
      • The EMBRAVE3 registrational study for SCN2A GoF-DEE is on track to initiate in mid-2025. Cohort 1 of the study will enroll up to 40 patients ages 2 to 18 years, 1:1 between drug and sham for a six-month period with once monthly intrathecal dosing of 1 mg per visit, with a primary endpoint measuring reduction in seizure frequency. Cohorts 2 and 3 will evaluate patients from ages 1 to 2 and 0 to 1 years, respectively.
      • In April 2025, the experience of an emergency-use patient dosed on elsunersen was published in Nature Medicine [linkl providing preliminary insights on the safety and efficacy of elsunersen in a preterm infant with early-onset SCN2A developmental and epileptic encephalopathy.
    • Praxis remains on track to nominate a development candidate for each of its early stage ASO therapeutic initiatives in 2025
      • PRAX-080: Focused on targeting PCDH19 mosaic expression
      • PRAX-090: Designed to address SYNGAP1 loss-of-function (LoF) mutations, a leading cause of severe intellectual disability and epilepsy in DEEs.
      • PRAX-100: Targeting SCN2A LoF mutations, the predominant genetic link to de novo autism spectrum disorders (ASD).

    First Quarter 2025 Financial Results:

    As of March 31, 2025, Praxis had $472.0 million in cash, cash equivalents and marketable securities, compared to $469.5 million in cash, cash equivalents and marketable securities as of December 31, 2024. The increase of $2.5 million is primarily attributable to net proceeds from at-the-market offerings of common stock offset by cash used in operating activities. The Company's cash, cash equivalents and marketable securities as of March 31, 2025 are expected to fund operations into 2028.

    Praxis did not recognize any collaboration revenue during the three months ended March 31, 2025, compared to $0.4 million during the three months ended March 31, 2024. The decrease of $0.4 million is related to its Option and License Agreement with UCB. In December 2024, UCB exercised its option to in-license global development and commercialization rights for a KCNT1 small molecule development candidate, and as such, Praxis has no further research service obligations under the terms of the Option and License Agreement.

    Research and development expenses were $60.8 million for the three months ended March 31, 2025, compared to $27.0 million for the three months ended March 31, 2024. The increase in research and development expenses of $33.8 million was primarily attributable to $29.9 million in increased expenses related to the Company's Cerebrum™ platform, $1.9 million in increased personnel expenses, and $1.9 million in increased indirect expenses.

    General and administrative expenses were $13.9 million for the three months ended March 31, 2025, compared to $15.3 million for the three months ended March 31, 2024. The decrease in general and administrative expenses of approximately $1.4 million was primarily due to $2.8 million in decreased personnel-related expenses, partially offset by a $1.4 million increase in indirect expenses.

    Praxis reported a net loss of $69.3 million for the three months ended March 31, 2025, including $8.8 million of stock-based compensation expense, compared to $39.6 million for the three months ended March 31, 2024, including $14.5 million of stock-based compensation.

    As of March 31, 2025, Praxis had 20.3 million shares of common stock outstanding.

    About Vormatrigine (PRAX-628)

    Vormatrigine is a next-generation, functionally selective small molecule targeting the hyperexcitable state of sodium-channels in the brain that is currently being developed as a once daily, oral treatment for adult focal onset seizures and generalized epilepsy. Preclinical data demonstrates vormatrigine is differentiated from standard of care, with the potential to be best-in-class for focal epilepsy. In vitro, vormatrigine has demonstrated superior selectivity for disease-state NaV channel hyperexcitability. In vivo studies of vormatrigine have demonstrated unprecedented potency in the maximal electroshock seizure (MES) model, a highly predictive translational model for efficacy in focal epilepsy. Data from the study demonstrated that vormatrigine can be safely dosed in healthy subjects to greater than 20 times the predicted human equivalent of the rodent MES EC50. To learn more about the POWER1 study please visit POWER1 study.

    About Relutrigine (PRAX-562)

    Relutrigine is a first-in-class small molecule in development for the treatment of developmental and epileptic encephalopathy (DEE) as a preferential inhibitor of persistent sodium current, shown to be a key driver of seizure symptoms in early onset SCN2A-DEE and SCN8A-DEE. Relutrigine's mechanism of sodium channel blocking is consistent with superior selectivity for disease state sodium channel (NaV) channel hyperexcitability. In vivo studies of relutrigine have demonstrated dose-dependent inhibition of seizures up to complete control of seizure activity in SCN2A, SCN8A and other DEE mouse models. Relutrigine has been generally well-tolerated in three Phase 1 studies and has demonstrated biomarker changes indicative of NaV channel blocking effects. Relutrigine has received ODD and RPDD from the FDA, and ODD from the European Medicines Agency for the treatment of SCN2A-DEE and SCN8A-DEE and RPDD for Dravet Syndrome from the FDA. To learn more about the EMBOLD study, please visit EMBOLD study.

    About Ulixacaltamide

    Ulixacaltamide is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical (CTC) circuit correlated with tremor activity. Ulixacaltamide, the most advanced program within Praxis' Cerebrum™ small molecule platform, is currently in late-stage development for the treatment of essential tremor, Essential3 study.

    About Elsunersen (PRAX-222)

    Elsunersen is an antisense oligonucleotide (ASO) designed to selectively decrease SCN2A gene expression, directly targeting the underlying cause of early-seizure-onset SCN2A-DEE to treat seizures and other symptoms in patients with gain-of-function SCN2A mutations. In vitro studies of elsunersen have demonstrated reduction in both SCN2A gene expression and protein levels. In vivo, elsunersen has demonstrated significant, dose-dependent reduction in seizures, improvement in behavioral and locomotor activity and increased survival in SCN2A mouse models, with potential to be the first disease-modifying treatment for SCN2A-DEE. Elsunersen has received ODD and RPD from the FDA, and ODD and PRIME designations from the European Medicines Agency for the treatment of SCN2A-DEE. The elsunersen program is ongoing under a collaboration with Ionis Pharmaceuticals, Inc., and RogCon, Inc. To learn more about the EMBRAVE study, please visit https://www.embravestudy.com/.

    About Praxis

    Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Praxis' future expectations, plans and prospects, including, without limitation, statements regarding the anticipated timing of our clinical trials, the development of our product candidates and plans to initiate new clinical programs, the anticipated timing of regulatory submissions and interactions and our projected cash runway, as well as other statements containing the words "anticipate," "believe," "continue," "could," "endeavor," "estimate," "expect," "anticipate," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," "target," "will" or "would" and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995.

    The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical trials; preliminary analyses from ongoing studies differing materially from final data from preclinical studies and completed clinical trials; the expected timing of clinical trials, data readouts and the results thereof, and submissions for regulatory approval or review by governmental authorities; regulatory approvals to conduct trials; and other risks concerning Praxis' programs and operations as described in its Annual Report on Form 10-K for the year ended December 31, 2024 and other filings made with the Securities and Exchange Commission. Although Praxis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

    PRAXIS PRECISION MEDICINES, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Amounts in thousands)

    (Unaudited)

     
     March 31,

    2025
     December 31,

    2024
    Assets 
    Cash and cash equivalents$165,567  $215,372 
    Marketable securities 306,456   254,156 
    Prepaid expenses and other current assets 5,584   11,805 
    Property and equipment, net 247   230 
    Operating lease right-of-use assets 882   1,131 
    Other non-current assets —   416 
    Total assets$478,736  $483,110 
    Liabilities and stockholders' equity  
    Accounts payable$22,909  $12,528 
    Accrued expenses 15,547   23,763 
    Operating lease liabilities 1,066   1,369 
    Common stock 14   14 
    Additional paid-in capital 1,344,577   1,281,522 
    Accumulated other comprehensive gain 659   654 
    Accumulated deficit (906,036)  (836,740)
    Total liabilities and stockholders' equity$478,736  $483,110 



    PRAXIS PRECISION MEDICINES, INC.
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (Amounts in thousands, except share and per share amounts)

    (Unaudited)
     
     Three Months Ended

    March 31,
      2025   2024 
    Collaboration revenue$—  $431 
    Operating expenses:   
    Research and development 60,806   26,984 
    General and administrative 13,922   15,333 
    Total operating expenses 74,728   42,317 
    Loss from operations (74,728)  (41,886)
    Other income:   
    Other income, net 5,432   2,333 
    Total other income 5,432   2,333 
    Net loss$(69,296) $(39,553)
    Net loss per share attributable to common stockholders, basic and diluted$(3.29) $(2.84)
    Weighted average common shares outstanding, basic and diluted

     21,055,834

       13,904,374 


    Investor Contact:
    Praxis Precision Medicines
    [email protected]
    857-702-9452
    
    Media Contact:
    Dan Ferry
    Life Science Advisors
    [email protected]
    617-430-7576

    Primary Logo

    Get the next $PRAX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PRAX

    DatePrice TargetRatingAnalyst
    6/2/2025$97.00Outperform
    Oppenheimer
    5/7/2025$80.00Buy
    Chardan Capital Markets
    3/3/2025$120.00 → $105.00Buy
    H.C. Wainwright
    2/11/2025$111.00Buy
    Deutsche Bank
    8/5/2024$134.00Outperform
    Oppenheimer
    6/24/2024$145.00Buy
    Needham
    6/18/2024$155.00Buy
    Guggenheim
    5/1/2024$117.00Outperform
    Robert W. Baird
    More analyst ratings

    $PRAX
    SEC Filings

    See more
    • Praxis Precision Medicines Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)

      6/27/25 4:47:11 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.

      SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

      6/6/25 12:00:34 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.

      SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

      5/15/25 4:35:30 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, July 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on July 1, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 2,100 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the empl

      7/2/25 5:00:00 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on June 2, 2025, the Compensation Committee of Praxis' Board of Directors granted a restricted stock unit award covering 750 shares of its common stock to one new non-executive employee under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit award was granted as inducement material to the employee's entering into em

      6/4/25 5:00:00 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines to Participate in Upcoming Conferences

      BOSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in three upcoming investor conferences: Praxis management will be participating in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference, taking place at NASDAQ on Tuesday, May 20th, at 9:30am ET. A webcast of the fireside chat will be available through this link.Praxis management will also be participating in the Mizuho

      5/20/25 8:00:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer resumed coverage on Praxis Precision Medicines with a new price target

      Oppenheimer resumed coverage of Praxis Precision Medicines with a rating of Outperform and set a new price target of $97.00

      6/2/25 8:54:06 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Praxis Precision Medicines with a new price target

      Chardan Capital Markets initiated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $80.00

      5/7/25 8:38:09 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Praxis Precision Medicines with a new price target

      H.C. Wainwright reiterated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $105.00 from $120.00 previously

      3/3/25 7:53:12 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Mitchell Dean J

      4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

      6/27/25 4:55:31 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Young William D

      4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

      6/27/25 4:55:21 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Norden Gregory

      4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

      6/27/25 4:55:11 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Desimone Jill bought $25,375 worth of shares (14,500 units at $1.75) (SEC Form 4)

      4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

      10/10/23 7:41:39 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Financials

    Live finance-specific insights

    See more
    • GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

      Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen

      2/18/25 6:00:00 AM ET
      $BIIB
      $PRAX
      $STOK
      $WGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Retail: Computer Software & Peripheral Equipment
    • Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

      Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 Registrational Cohort 2 of EMBOLD study recruiting following unprecedented seizure freedom seen in positive topline EMBOLD results for Cohort 1 in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) Vormatrigine (PRAX-628) on track for topline from POWER1 study in focal epilepsy and RADIANT study in focal and generalized epilepsy in 2025 Maintains runway into 2027 BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic i

      11/6/24 7:30:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

      BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the third quarter ended September 30, 2024, before the financial markets open on Wednesday, November 6, 2024. The Company will host a live webcast the same morning at 8am ET, which can be accessed by visiting this registration link. This live webcast will also be available through the Events & Presentations page of the Investors + Media se

      11/1/24 8:00:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

      SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

      11/14/24 7:53:30 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

      SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

      11/14/24 5:50:15 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

      SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

      11/14/24 5:46:12 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Leadership Updates

    Live Leadership Updates

    See more
    • Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results

      PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide therapeutic window Cash and investments of $165.4 million as of June 30, 2022 supports runway into 1Q24 BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the second quarter of 2022

      8/8/22 4:01:00 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone

      BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the appointment of Jill DeSimone to its board of directors. "We are very excited to have Jill join the Praxis board of directors. She is an ideal fit for the Praxis board with her impressive background as a global business leader for multi-billion-dollar products, unique insights into product strategy and portfolio prioritization, and breadth of experience advocating for excellence

      5/23/22 9:00:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Announces Management Team Appointments

      BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced the appointment of Megan Sniecinski as chief business officer and provided key updates on members of the executive leadership team. Praxis has promoted Alyssa Wyant to chief regulatory and quality officer and Karl Hansen, Ph.D., to chief technical operations officer. In addition, chief scientific officer and co-founder, Steven Petrou, Ph.D., has decided to fully dedicate his time to Praxis upon stepping

      12/2/21 7:00:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care